News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
Sarah Sammons Highlights 77% Response Rate with Carboplatin, Bevacizumab, and PD-1 Inhibitors in TNBC Brain Metastases
Sarah Sammons/medicine.duke.edu
May 31, 2025, 13:44

Sarah Sammons Highlights 77% Response Rate with Carboplatin, Bevacizumab, and PD-1 Inhibitors in TNBC Brain Metastases

Sarah Sammons, Breast Medical Oncologist and Senior Physician at Dana-Farber’s Breast Oncology Center, shared a post on X:

“Building off of Nancy Lin and Dr Pablo Leone’s data with carboplatin/bevacizumab in brain metastases.
77% intracranial response rate of carbo, bev, and PD-1 inhibition in TNBC brain metastases shows excellent potential.
Time to try this with bispecifics.”

Sarah Sammons

More posts featuring ASCO25.

ASCO25 Bevacizumab brain metastases cancer carboplatin OncoDaily Oncology PD-1 inhibitors Sarah Sammons TNBC
Special Coverage
Blog
May 31, 2025, 13:44
Sarah Sammons Highlights 77% Response Rate with Carboplatin, Bevacizumab, and PD-1 Inhibitors in TNBC Brain Metastases
Blog
May 31, 2025, 13:32
Petros Grivas: Congrats to All Conquer Cancer, the ASCO Foundation Young Investigator Awards Recipients
Blog
May 31, 2025, 13:12
Paolo Tarantino: Join a Comprehensive Symposium on the Present and Future of ADCs in Breast Oncology
Blog
May 31, 2025, 13:10
Lobular Breast Cancer IRL Advocates for Standardised Breast Density Reporting in Ireland
Science
May 31, 2025, 12:57
Sameer Rastogi Shared Early Results from SORASTOP Trial on Discontinuing Sorafenib in Desmoid Tumors
Blog
May 31, 2025, 12:52
Fumiko Ladd Chino: Seeing Friends, Colleagues, and Collaborators Who Live in Other Places is The Best Part of ASCO
Career
May 31, 2025, 12:32
Margarita Dionysiou Awarded St. Baldrick’s Fellowship for Leukemia Research - Johns Hopkins Kimmel Cancer Center
Blog
May 31, 2025, 12:22
Giselle Sholler: The Best Part about ANR is Connecting with Friends and Colleagues, New and Old
Insight
May 31, 2025, 12:13
E. Shyam P. Reddy: Researchers Identified a New Biomarker to Predict Outcomes in KRAS G12C-Mutated NSCLC
Oncolibrary
May 31, 2025, 11:53
KANDLELIT-001 Trial Demonstrates Promising Activity of MK-1084 in KRAS G12C–Mutant Colorectal Cancer at ASCO 2025
Blog
May 31, 2025, 11:32
Jame Abraham: Looking Forward to Seeing You at ASCO 2025 in Chicago
Blog
May 31, 2025, 11:04
Paolo Tarantino: Interesting Results From a 1L Trial of CDK4/6 Inhibitors in Triple-Positive MBC at ASCO 2025